Cho Provides Background on the Multiple Myeloma Research Foundation’s CureCloud Study

July 16, 2020
Hearn Cho, Md, PhD

Hearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.

Hearn Jay Cho, MD, PhD, chief medical officer, Multiple Myeloma Research Foundation (MMRF), and associate professor at Mount Sinai Hospital Ruttenberg Treatment Center, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.

The CureCloud study (NCT03657251) launched on July 14th and is open to most patients in the United States with active multiple myeloma (MM) that requires treatment, explains Cho. The study will collect real-world, long-term data from 5000 patients with MM. The CureCloud protocol was developed through a collaborative effort between the research, clinical, and data teams at the MMRF.

The 2 over-arching goals of the CureCloud study are to provide genomic information about their disease subtype and appropriate clinical trials to patients with MM and their physicians, and to allow access to this aggregated real-world data to all patients with MM, physicians, and researchers. In both cases, these data will enable more personalized and informed treatment decisions.

Patients donate their genomic data by consenting online to an in-home blood draw that is analyzed in a first-of-its-kind cell-free DNA sequencing assay/blood biopsy using a unique 70-gene panel. Patients also consent to donate their electronic medical records, which are extracted and paired with their genomic data in the secure, deidentified CureCloud database. Both patients and their physicians will receive a detailed report on their genomic findings, and a list of clinical trials that may be appropriate for the patient.

Importantly, aggregated genomic, clinical, and (in the future) immune data will be visualized in a portal, where both patients and physicians can see treatment outcomes for patients with defined clinical and/or genomic characteristics. These data may be used to make more personalized and informed treatment decisions for patients with these same characteristics.

To find out more about the CureCloud study, go to https://mmrfcurecloud.org/physicians